Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Prostatic Neoplasms 3Leukemia, Myeloid, Acute 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Lung Neoplasms 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Vulvar Neoplasms 1Vaginal Neoplasms 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Retinoblastoma 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neuroblastoma 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Liver Neoplasms 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Gliosarcoma 1Glioblastoma 1Gallbladder Neoplasms 1Esophageal Neoplasms 1

Interventions

Lenalidomide 2Watchful Waiting 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Observation 1Melphalan 1Celecoxib 1AH 111585 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Smoldering Multiple Myeloma × Watchful Waiting × Clear all
NCT01169337 2026-05-01

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
226 enrolled 16 charts
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡